文献速递新发突发、热带与寄生虫病

加纳沿海地区恶性疟原虫临床分离株的体外药物反应

Plasmodium falciparum isolates: ex vivo drug response.
PubMed 文献 · J Antimicrob Chemother · 2025-01-01

研究对66株来自无并发症疟疾患者的恶性疟原虫临床分离株进行体外药物敏感性检测,双氢青蒿素和青蒿琥酯均敏感,但部分虫株对lumefantrine和amodiaquine的IC50超过耐药参考切点,提示药物耐受表型出现。

要点

  • 加纳沿海恶性疟原虫临床分离株对双氢青蒿素和青蒿琥酯体外敏感。
  • 部分虫株对lumefantrine和amodiaquine的IC50超过耐药参考切点,提示敏感性下降。

核心结论

  • 加纳沿海临床分离株对常用ACT中的青蒿素衍生物仍敏感,但观察到对ACT伴侣药物lumefantrine和amodiaquine敏感性降低,提示药物耐受表型出现。
  • 需要持续进行药物表型-基因型监测以支持加纳ACT疗效。

研究设计与样本

  • 研究测量了66株来自无并发症疟疾患者的临床分离株的体外敏感性,采用SYBR Green I生长抑制试验测定IC50,并用Oxford Nanopore扩增子测序评估pfcrt、pfmdr1和pfkelch13的已知耐药多态性。

主要发现

  • 临床分离株对双氢青蒿素和青蒿琥酯敏感。
  • 临床分离株对lumefantrine和amodiaquine的敏感性分布广泛,部分寄生虫的IC50值超过lumefantrine耐药参考切点150 nM和amodiaquine耐药参考切点60 nM,提示药物敏感性降低。
  • 62.1%的寄生虫携带pfmdr1 N86和184F单倍型。
  • 没有临床分离株携带已知介导青蒿素部分耐药的 validated pfkelch13 突变。

关键数值与推荐

  • lumefantrine耐药参考切点为150 nM,amodiaquine耐药参考切点为60 nM。
  • 62.1%的寄生虫携带pfmdr1 N86和184F单倍型。
  • 没有临床分离株携带 validated pfkelch13 突变。

临床怎么用

  • 在加纳沿海地区,常用ACT中的青蒿素衍生物对恶性疟原虫临床分离株体外仍敏感。
  • 对lumefantrine和amodiaquine敏感性降低的迹象提示需要持续监测药物表型-基因型以支持ACT疗效。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: While artemisinin-based combination therapies (ACTs) are effective in sub-Saharan Africa, clinical isolates that are refractory to artemisinin derivatives are emerging in East Africa and ACT partner drugs are becoming less effective in West Africa. We investigated the ex vivo responses of Plasmodium falciparum clinical isolates to frontline antimalarials and the contribution of validated molecular markers of antimalarial drug resistance. METHODS: Ex vivo susceptibility was measured for 66 clinical isolates collected from uncomplicated malaria patients. IC50 was measured for dihydroartemisinin, artesunate, lumefantrine, amodiaquine and chloroquine using a SYBR Green I growth inhibition assay. We also assessed known drug resistance-mediating polymorphisms in pfcrt, pfmdr1 and pfkelch13 using Oxford Nanopore amplicon sequencing. RESULTS: P. falciparum clinical isolates were susceptible to dihydroartemisinin and artesunate. Clinical isolates showed a wide distribution of susceptibility to lumefantrine and amodiaquine, with some parasites having IC50 values above reference cut-offs for resistance to lumefantrine (150 nM) and amodiaquine (60 nM), suggesting decreased drug susceptibility. Ninety-seven percent of the isolates carried WT pfcrt K76 and pfmdr1 N86 alleles, reported to mediate reduced response to lumefantrine and artemether/lumefantrine. pfmdr1 N86 and 184F haplotype was carried by 62.1% of parasites. None of the clinical isolates carried validated pfkelch13 mutations known to mediate artemisinin partial resistance. CONCLUSIONS: Clinical isolates from coastal Ghana remain susceptible to artemisinin derivatives in commonly used ACTs in Ghana. However, we observed lower susceptibility to the ACT partner drugs lumefantrine and amodiaquine, suggesting the emergence of drug-tolerance phenotypes. Consistent surveillance of drug phenotype-genotype is needed to support ACT efficacy in Ghana.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Adika E, Saiid S, Amoako EK, et al. Plasmodium falciparum isolates: ex vivo drug response. J Antimicrob Chemother. 2025. PMID: 40343740. doi:10.1093/jac/dkaf129

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。